INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 135 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2018. The put-call ratio across all filers is 0.27 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $649,000 | -39.6% | 18,921 | -86.9% | 0.03% | -40.7% |
| Q3 2019 | $1,075,000 | +149.4% | 143,921 | +333.2% | 0.05% | +125.0% |
| Q2 2019 | $431,000 | +31.8% | 33,221 | +23.9% | 0.02% | +20.0% |
| Q1 2019 | $327,000 | -33.3% | 26,818 | -37.6% | 0.02% | -37.5% |
| Q4 2018 | $490,000 | -42.2% | 42,996 | +10.0% | 0.03% | -17.9% |
| Q3 2018 | $848,000 | -19.7% | 39,096 | -34.6% | 0.04% | -9.3% |
| Q2 2018 | $1,056,000 | -10.0% | 59,796 | -26.2% | 0.04% | -17.3% |
| Q4 2017 | $1,173,000 | -47.3% | 81,010 | -42.6% | 0.05% | -54.4% |
| Q3 2017 | $2,227,000 | +246.9% | 141,157 | +173.1% | 0.11% | +235.3% |
| Q2 2017 | $642,000 | -60.9% | 51,693 | -48.9% | 0.03% | -55.3% |
| Q1 2017 | $1,644,000 | +9.7% | 101,200 | +1.9% | 0.08% | -14.6% |
| Q4 2016 | $1,498,000 | – | 99,300 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 640,000 | $25,626,000 | 6.33% |
| Redmile Group, LLC | 1,322,592 | $52,957,000 | 4.01% |
| SENZAR ASSET MANAGEMENT, LLC | 556,224 | $22,271,209,000 | 3.24% |
| RA Capital Management | 314,349 | $12,587,000 | 1.81% |
| WALL STREET ASSOCIATES | 205,657 | $8,235,000 | 1.58% |
| Parametrica Management Ltd | 5,400 | $216,000 | 1.36% |
| Rhenman & Partners Asset Management AB | 165,000 | $6,607,000 | 1.05% |
| EAM Investors, LLC | 95,168 | $3,811,000 | 0.60% |
| Rock Springs Capital Management LP | 180,000 | $7,207,000 | 0.58% |
| WASATCH ADVISORS LP | 1,085,973 | $43,482,000 | 0.58% |